Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Daily News

Top General Cardiology and Prevention News of 2024

Caitlin E. Cox

December 30, 2024

News Daily News

FINEARTS-HF Analysis Supports Finerenone’s Value in HFpEF With Obesity

L.A. McKeown

December 13, 2024

News Daily News

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Top-line Results

Michael O'Riordan

December 04, 2024

News Daily News

CMS Proposal Would Expand Medicare, Medicaid Coverage for GLP-1 Drugs

Todd Neale

November 27, 2024

News Daily News

SUMMIT Meets Primary Endpoint for Safety, Efficacy of Tirzepatide: Topline Results

Yael L. Maxwell

August 01, 2024

News Daily News

Semaglutide Has Similar Benefits in Women and Men With HFpEF

Todd Neale

June 26, 2024

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

Todd Neale

December 22, 2023

News Daily News

Who Benefits Most From Semaglutide and How Long Will That Take?

Shelley Wood

December 19, 2023

News Daily News

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

L.A. McKeown

April 19, 2023

News Daily News

Study Debunks Obesity Paradox in HF, Encourages BMI Alternatives

L.A. McKeown

March 24, 2023

News Daily News

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Michael O'Riordan

December 30, 2022

News Daily News

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

Michael O'Riordan

April 26, 2021

News Daily News

Eating More Ultraprocessed ‘Junk’ Food Linked to Higher CVD Risk

Michael O'Riordan

March 23, 2021

News Daily News

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Caitlin E. Cox

August 15, 2018

Advertisement

Top General Cardiology and Prevention News of 2024

FINEARTS-HF Analysis Supports Finerenone’s Value in HFpEF With Obesity

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Top-line Results

CMS Proposal Would Expand Medicare, Medicaid Coverage for GLP-1 Drugs

SUMMIT Meets Primary Endpoint for Safety, Efficacy of Tirzepatide: Topline Results

Semaglutide Has Similar Benefits in Women and Men With HFpEF

AHA Selects 2023’s Leading Cardiovascular Research

Who Benefits Most From Semaglutide and How Long Will That Take?

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

Study Debunks Obesity Paradox in HF, Encourages BMI Alternatives

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

Eating More Ultraprocessed ‘Junk’ Food Linked to Higher CVD Risk

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content